DocGo – Allegations of Fraudulent Billing Practices & Forging of Documents

Fuzzy Panda Research has released a damning report on DocGo (NASDAQ: DCGO), claiming former employees have revealed widespread Medicare fraud, document forgery, and a "cover-up rather than comply" culture that could devastate the mobile healthcare provider's future.

Ticker: DCGO (NASDAQ)
Research Firm: Fuzzy Panda Research
Report URL: https://fuzzypandaresearch.com/docgo-employees-allege-medicare-fraud/
Position Disclosure: Fuzzy Panda Research and its affiliates hold a short position in DocGo (DCGO) and stand to profit if the company's share price declines. Readers should weigh this financial interest accordingly when evaluating the report's claims and conclusions.

Why It Matters

Former employees allege systematic Medicare fraud including billing for COVID tests never performed and forging patient signatures
DocGo faces multiple government investigations including from NY Attorney General, Governor's Office, and NYC Comptroller
Accounts receivable surged 160% YoY while revenue grew only 80%, with a $46M operating cash outflow in Q3 2023
Hidden liabilities exceeding $100M uncovered in a secretive "ABC liquidation" of DocGo's California subsidiary
Management team riddled with red flags: former CEO resigned after falsifying academic credentials; CFO linked to past fraud cases
NYC's $432M no-bid migrant contract under intense scrutiny for wasteful spending and potential related-party transactions

The Big Picture

DocGo allegedly instructed EMTs to "make the call billable" by fabricating or embellishing documentation
Company decreased provision for doubtful accounts from 8.6% to just 2.3% despite skyrocketing receivables
Former employees report a culture of retaliation against whistleblowers who raised ethical concerns
Numerous family members of executives employed at the company, raising concerns about nepotism and conflicts of interest
DocGo signed a $31.2M hotel master lease before securing the NYC migrant contract, raising questions about pre-arranged deals
The company's "AI subsidiary" reportedly has only one employee and no patents despite technology claims

FAQs

What specific fraudulent activities does Fuzzy Panda allege DocGo committed?

According to the report, former employees allege DocGo engaged in billing for COVID tests never performed, forging patient signatures, falsifying medical records, and systematically coaching EMTs to embellish documentation to maximize billable services.

Who is investigating DocGo currently?

Multiple government agencies are investigating DocGo, including the New York Attorney General's Office, the Governor's Office, and the NYC Comptroller. These investigations focus on potential fraud, wasteful spending, and misconduct related to their contracts, particularly the $432 million NYC migrant asylum contract.

What red flags exist in DocGo's financial reporting?

The report highlights several red flags, including a 160% year-over-year increase in accounts receivable while revenue grew at only 80%, a significant decrease in provisions for doubtful accounts (from 8.6% to 2.3%), and a $46 million operating cash flow outflow primarily due to an $84 million increase in accounts receivables.

What is the "ABC liquidation" mentioned in the report?

The ABC (Assignment for the Benefit of Creditors) liquidation is an alternative to formal bankruptcy that DocGo is allegedly using for its California subsidiary, Ambulnz Health LLC. According to a confidential source cited in the report, this process has uncovered liabilities exceeding $100 million, significantly more than DocGo has reported in its consolidated financial statements.

What concerns exist about DocGo's leadership?

The report details numerous leadership concerns, including: former CEO Anthony Capone resigned after falsifying academic credentials; current CFO Norm Rosenberg has ties to companies previously charged with fraud; board members have histories linked to failed penny stocks and fraud cases; and numerous family members of executives hold positions within the company, suggesting nepotism and potential conflicts of interest.

How does the NYC migrant contract factor into DocGo's business?

The $432 million no-bid contract to serve NYC migrants represents a significant portion of DocGo's current revenue but is only a one-year agreement. The report suggests this contract is under intense scrutiny for wasteful spending and potential related-party transactions, with investigations by multiple government agencies potentially threatening its continuation.

What parallels does the report draw to other companies?

The report compares DocGo's situation to Eargo, which saw a 90% stock price decline following similar allegations of Medicare fraud. It suggests DocGo may face a similar fate as investigations progress and the temporary revenue boost from the NYC contract expires.

What does the report say about DocGo's technology claims?

Despite positioning itself as a technology-driven healthcare provider with AI capabilities, the report claims DocGo's "AI subsidiary" has only one employee in Estonia and no patents. The company's consumer apps reportedly have minimal downloads and user reviews, undermining its claims of technological innovation.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://fuzzypandaresearch.com/docgo-employees-allege-medicare-fraud/, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.